Nothing said here yet.
to join the conversation.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Chief executive Warner Biddle said the therapy’s durability “exceeded even our expectations.”
Investing.com -- Kyverna Therapeutics Inc (NASDAQ:KYTX) shares rose nearly 10% in early trade Thursday following the release of positive one-year durability data for its miv-cel therapy in stiff person syndrome and generalized myasthenia gravis.
Kyverna Therapeutics (NASDAQ:KYTX) reported one-year topline data from its KYSA-8 registrational trial of miv-cel, or mivocabtagene autoleucel, in stiff person syndrome (SPS), alongside longer-term follow-up results from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG).
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc.
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel…
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-celEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc.